Regeneron And TriNetX Collaborate To Integrate Genomic And Real-World Data For Advanced Drug Discovery And Digital Health

Regeneron Pharmaceuticals, Inc. has entered into a strategic collaboration with TriNetX to strengthen its drug discovery and development capabilities while advancing future digital health solutions. Through this partnership, Regeneron will gain exclusive access to integrate its large-scale genomic and proteomic datasets with TriNetX’s extensive phenotypic data network, which includes information from approximately 300 million de-identified patients worldwide.

“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” said Jeff Margolis, TriNetX Executive Chairman. “Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.”

As part of the agreement, TriNetX will provide secure, licensed access to its global health data, including records from around 170 million individuals in the United States. Regeneron will use privacy-preserving technologies to match portions of this anonymized data with genomic and proteomic information generated by the Regeneron Genetics Center. All data integration will adhere strictly to regulatory standards such as HIPAA and GDPR, ensuring patient privacy and compliance.

"This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines. "TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale. Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease."

The Regeneron Genetics Center has already built one of the world’s largest databases of EHR-linked sequencing and proteomics data through collaborations with over 150 global partners. By combining this resource with TriNetX’s vast phenotypic dataset, the collaboration is expected to significantly enhance research capabilities, accelerate therapeutic development, and support the training of advanced AI models for next-generation healthcare solutions.

"We are looking forward to working with the TriNetX team," said Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer. "Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission."

In addition to data integration, the partnership includes a financial commitment, with Regeneron planning to invest up to $200 million in TriNetX. This move underscores the strategic importance of large-scale data ecosystems in driving innovation across drug development and digital health.

Also Read

Regeneron Pharmaceuticals, Inc. Receives FDA Approval To Extend Dosing Intervals For EYLEA HD In Wet AMD And Diabetic Macular Edema